UK markets open in 3 hours 49 minutes

Aerie Pharmaceuticals, Inc. (AERI)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
16.21+0.09 (+0.56%)
At close: 4:00PM EDT
16.06 -0.15 (-0.93%)
After hours: 04:13PM EDT
Sign in to post a message.
  • V
    Viacheslav
    Good company! Why do we fall?
  • D
    David
    Any up-date on recent script data?? (positive or negative) Jim ???
  • Y
    Yahoo Finance Insights
    Aerie Pharmaceuticals is down 6.24% to 17.07
  • Y
    Yahoo Finance Insights
    Aerie Pharmaceuticals is down 6.74% to 16.05
  • D
    David
    Can we give our product away for say 50 to 70 bucks per bottle. That way, we can never turn a profit,...but wowsers, we sure would be pushing product out the door. Maybe we can mgmt. more money & pay the mediocre sales force more money too. Lets just give it all away.!!
  • J
    Jim
    New Corporate Presentation on AERI website. Weekly RXs setting record high sales . Last week 22000 plus bottles @ $80 per.
  • D
    David
    This company's management team can't seem to Get Product Rolling. there's always some sort of excuse
  • D
    David
    Down -10% or more, in just basically a week of trading. (crickets here)
  • V
    Vs
    My calculation based on their presentation chart put total around 230K bottle
    We going to have $19M+ in revenue this quarter ($85/bottle rate) which actually very very good given all Eye clinic have impact due to covid 19.

    I think recent script data indicate inflection point much closer for Rockalatan. Covid19 may be keeping it from going much higher but given how important Glucoma treatment, it will sell.
  • D
    David
    Well....At least Oppenheimer is maintaining an Outperform rating and $24 price target, while Needham - on July 17th, assigned AERI a BUY rating and price target of 32... so....there's THAT. Here is the link: https://www.markets.co/analysts-offer-insights-on-healthcare-companies-aerie-pharma-nasdaq-aeri-and-quest-diagnostics-nyse-dgx/262565/
    Analysts have been eager to weigh in on the Healthcare sector with new ratings on Aerie Pharma (AERI – Research
    Analysts have been eager to weigh in on the Healthcare sector with new ratings on Aerie Pharma (AERI – Research
    www.markets.co
  • V
    Vs
    My bottle count was spot on. While revenue $18 due to lower per bottle cost, Important part is volume and market share. Both they are gaining.

    I think once they have very good coverage on Medicare D, We may acheive 15% market share very easily in just 2 year.
    So What 15% share even at $70 Bottle would look like in USA?
    We talking about 8M bottle x 70 = $560M

    So bottles are way more important than per bottle price. I think keeping lower price they can gain market share quickly as payer would have less resistant to go for cheaper alternative.
  • U
    Uber
    Seems not to be much of a following here but if anyone is willing to engage, I'd like to know what your long thesis is. My take on the pps is that Mr. market does not want to wait for positive fcf which may be 2-3 years away despite product on the market. Thoughts?
  • B
    BioPharmaLand
    Updates from the most recent corporate presentation:
    - A sharp increase in the actual weekly sale (see slide 7).
    https://investors.aeriepharma.com/node/12031/html
    The question is if the price-per-bottle is as before? If yes, this may change their income projection for 2019.
    SEC Filing | Aerie Pharmaceuticals, Inc
    investors.aeriepharma.com
  • S
    Stephen
    See my earlier posts below. Did anyone else listen to the conference call and how not one of the analysts asked the tough questions of management? Why didn't one of the analysts ask why NO ONE in the company has bought their own stock at all time yearly lows???? Hoping that another Pharma or fund takes them out very soon before they finalize a partner agreement in Europe. Management is building a huge empire on a tiny spec of land - way too much overhead - other competitors could do so much better.
  • A
    Anil
    If I was running this company, I would be nervous and take necessary steps to gain the confidence of the stakeholders.
  • A
    Amer Yasin
    So far I have lost almost 45% of my total investment approximately. Is there an expert in here who can give me a true insight instead letting me know the products are very promising. Shall I keep my shares or sell them?
  • D
    Deerslayer
    This pharmaceutical is a whole new class of glaucoma drug and it has been an incredible success story and revolutionary in the treatment of glaucoma. Investors will realize this soon, once this panic selling stops. This is a unique opportunity to get in on a special company’s product which is a phenomenal success story in the fields of ophthalmology and Optometry. It is saving many patients from having to go straight to surgery. It’s just a matter of town.
  • U
    Uber
    10 sell-side analysts cover AERI and 9 of them are either "buy", or "strong buy". The one guy at Bank of America who was "neutral" goes to "sell" and it tanks the stock by 13%? Interesting.
  • a
    accu
    $48.70 buying here. New glaucoma medicines Rhopressa and Roclatan. No new medicines in decades until now.
  • S
    Steve
    I like the company but as of today they only have have around 87 million in cash left and burning through 15-18 million a month. Add in 80 million in debt they need to raise capital in very near future. Lower sales guidance by 40 percent doesnt help anything either